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ABSTrACT
Background: The embolization of atheroma/thrombus frag-
ments during percutaneous coronary intervention (PCI) causes 
microcirculatory perfusion disturbances. The new MGuardTM, 
a mesh- based bare- metal stent, demonstrated efficacy in the 
prevention of embolic complications during primary PCI. 
However, the late clinical outcome of patients treated with the 
MGuardTM stent remains unknown. Methods: A series of 65 
patients with de novo coronary lesions treated with MGuardTM 
stent was analyzed. Baseline clinical data, procedure and late 
clinical follow- up (mean duration, 2.6 ± 1.4 years) data were 
collected retrospectively by a review of medical records and/ 
or direct telephone contact. results: Mean age was 66.1 ± 13.7 
years, 32.3% of patients were diabetic, 49.2% had a previ-
ous acute myocardial infarction (AMI), and 44.6% presented 
with acute coronary syndrome. Two thirds of the lesions were 
located in a saphenous vein graft, almost half of the lesions 
had thrombus and most were classified as type B2/C. The 
MGuardTM stent was successfully implanted in all cases. At 
the end of the procedure, TIMI 3 flow was achieved in 93.4% 
and angiographic success was 91.8%. In the late clinical 
follow- up, adverse event rates included cardiac death in 6.2%, 
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rESUMO
Evolução Tardia de Pacientes com Lesões  
Coronárias Complexas Tratados com o  
Novo Stent Metálico MGuardTM
Introdução: A embolização de fragmentos de ateroma/trombo 
durante a intervenção coronária percutânea (ICP) ocasiona 
distúrbios de perfusão da microcirculação. O novo stent 
MGuardTM, que é revestido com uma rede de polietileno, 
demonstrou eficácia na prevenção de complicações embóli-
cas durante a ICP primária. No entanto, a evolução clínica 
tardia de pacientes tratados com o stent MGuardTM permanece 
desconhecida. Métodos: Uma série de 65 pacientes portadores 
de lesões coronárias de novo tratados com o stent MGuardTM 
foi analisada. Os dados clínicos basais, do procedimento e do 
seguimento clínico tardio (média de tempo, 2,6 ± 1,4 anos) 
foram coletados retrospectivamente por meio da revisão de 
prontuários médicos e/ou contato telefônico direto. resulta-
dos: A média de idade foi de 66,1 ± 13,7 anos, 32,3% eram 
diabéticos, 49,2% tinham infarto agudo do miocárdio (IAM) 
prévio, e 44,6% apresentaram se com síndrome coronária 
aguda. Dois terços das lesões estavam localizados em pon-
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non fatal AMI in 9.2%, target lesion revascularization in 9.2% 
and definite/probable stent thrombosis in 1.5%. Conclusions: 
The late follow -up of patients with complex coronary lesions 
treated with the MGuardTM stent demonstrated low rates of 
target lesion revascularization and stent thrombosis.
 
 
 
 
 
DESCrIPTOrS: Angioplasty. Stents. Embolism. Coronary 
thrombosis.
(Instituto Dante Pazzanese de Cardiologia, São Paulo, 
SP, Brazil). The study population included 65 patients 
(66 coronary lesions) submitted to PCI, whether elective 
or emergency, with MGuardTM stent implantation during 
the routine of the Invasive Cardiology Department be-
t ween 2007 and 2012. In general, the MGuardTM stent 
was considered for the treatment of patients with de 
novo coronary lesions in native vessel or bypass graft 
who had angiographic characteristics associated with 
instability, such as thrombus, ulcers and filling defects, 
and/or in the presence of acute coronary syndrome. The 
study patients were selected from the local database, 
and data collection was performed through review of 
medical records, medical reports, and angiograms, as 
well as by telephone contact.
Study device
The characteristics and specifications of the 
MGuardTM device have been previously reported.6 In 
summary, the MGuardTM stent incorporates a 316L, 
laser-cut, stainless steel metallic platform, coated or 
covered with a double network of microscopic poly-
ethylene terephthalate fibres, which are attached to 
metal struts (Figure 1). This network acts by trapping 
the material contained between the stent and the 
vessel wall, thus preventing the distal embolisation 
of atherothrombotic materials during implantation. 
The release system is low-profile balloon-expandable, 
compatible with 5F guide catheters.
Procedure
In general, PCIs were performed according to current 
guidelines. Pre- and/or post-dilation was performed at 
the surgeon’s discretion, as was the use of glycoprotein 
IIb/IIIa inhibitors. MGuardTM stents were available in 
diameters between 2.5 mm and 4 mm (with 0.5-mm 
intervals) and extensions between 12 mm and 40 mm. 
The treatment of non-target lesions in the target vessel 
or non-target vessel with bare-metal stent during the 
index procedure could be performed if necessary.
tes de safena, quase metade tinha presença de trombo e a 
maioria foi classificada como tipo B2/C. O stent MGuardTM 
foi implantado com sucesso em todos os casos. Ao final do 
procedimento, fluxo TIMI 3 foi alcançado em 93,4% e o 
sucesso angiográfico foi de 91,8%. No seguimento tardio, as 
taxas de eventos adversos incluíram óbito cardiovascular em 
6,2%, IAM não-fatal em 9,2%, revascularização da lesão-
alvo em 9,2% e trombose de stent definitiva/provável em 
1,5%. Conclusões: O seguimento tardio de pacientes com 
lesões coronárias complexas tratados com o stent MGuardTM 
demonstrou baixas taxas de revascularização da lesão alvo e 
de trombose do stent.
DESCrITOrES: Angioplastia. Stents. Embolia. Trombose 
coronária.
Distal embolisation of the atherothrombotic mate-rial during percutaneous coronary intervention (PCI) is an undesirable occurrence that leads to 
microvascular obstruction and reduction of myocardial 
perfusion,1 which may lead to periprocedural infarction, 
and consequently decrease in ventricular function and 
increase in cardiac mortality.2-4 Several therapeutic ap-
proaches, including the use of dedicated devices, have 
been tested in different clinical settings in order to 
prevent embolic complications. The results, however, 
were not consistent. Additionally, some percutaneous 
devices were associated with increased costs and 
procedure time.
The MGuardTM stent (Inspire MD – Tel Aviv, Israel) is 
a new low-profile metallic device, specifically designed 
for the prevention of distal embolisation during PCI, 
since its metal struts are covered by a double polymer 
network. Previous studies involving complex lesions with 
high thrombogenic potential (acute coronary syndrome, 
saphenous graft degeneration, and thrombus, among 
others) have demonstrated the efficacy of the MGuardTM 
stent in preventing embolic complications.5,6 Furthermore, 
the MGuardTM stent was superior to conventional stents 
(non-covered) in relation to target-vessel reperfusion in 
patients with acute myocardial infarction with ST-segment 
elevation (STEMI) undergoing primary PCI.7
Despite the promising clinical results obtained with 
the MGuardTM stent in several clinical series, the late 
evolution of patients with coronary artery disease treated 
with this device remains unknown. Therefore, this study 
aimed to evaluate the late follow-up (> six months) of 
a series of patients treated with the MGuardTM stent in 
the daily practice of a public tertiary institution.
MethodS
Study design and target population
The current analysis constitutes a retrospective 
observational study conducted in a single center 
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The pre-procedure dual antiplatelet therapy con-
sisted of acetylsalicylic acid 100 to 200 mg/day and 
loading dose of clopidogrel 300 mg, at least 24 hours 
before the procedure, or 600 mg if < 24 hours. After 
the intervention, acetylsalicylic acid 100 to 200 mg/day 
was prescribed indefinitely, and clopidogrel 75 mg/
day was maintained for at least six months. During the 
PCI, antithrombin therapy consisted of unfractionated 
heparin at a dose of 100 IU/kg (or 70 IU/kg in case of 
glycoprotein IIb/IIIa inhibitor use), aiming to achieve an 
activated clotting time > 250 sec (or between 200 and 
250 sec, in case of glycoprotein IIb/IIIa inhibitor use).
Angiographic analysis
The qualitative and quantitative angiographic ana-
lyses were performed offline by an experienced surgeon, 
following a pre-defined protocol. In general, the pre- 
and post-procedure cineangiographies were performed 
after intracoronary administration of nitroglycerin 
(50-200  µg) in at least two corresponding orthogonal 
views, and were stored in DICOM digital format. The 
morphological characteristics and the complexity of the 
lesions were defined according to the criteria of the 
modified classification system of the American College 
of Cardiology/American Heart Association (ACC/AHA). 
The coronary flow was determined according to the 
criteria of the Thrombolysis in Myocardial Infarction 
(TIMI) study. Angiographic complications during the 
procedure (dissection, slow flow, distal embolisation, 
no reflow phenomenon) were determined according to 
pre-established criteria and definitions. The analysis of 
quantitative coronary angiography (QCA) was performed 
using a dedicated computer program and semi-automatic 
detection of lumen borders (QAngio XA; Medis Med-
ical Imaging Systems – Leiden, The Netherlands). The 
tip of the guide catheter filled with contrast was used 
for calibration. The minimum lumen diameter and the 
reference vessel diameter, obtained by the interpolated 
reference, were used to calculate the diameter of the 
stenosis using the following formula: 
DS = (1 MLD / RVD) × 100
where DS = diameter of the stenosis, MLD = minimum 
lumen diameter, and RVD = reference vessel diameter. 
Immediate gain was defined as the difference in minimal 
lumen diameter pre- and post-procedure (post-procedural 
MLD – pre-procedure MLD). QCA analyses were re-
ported for the intra-stent segment and intra-segment, 
which included the intra-stent segment plus 5 mm of 
the proximal and distal borders of the stent.
Qualitative and quantitative angiographic analyses 
were performed in 61 of the 66 lesions, as the an-
giographic films were not available in five cases. All 
analyses were performed in the QCA laboratory of 
Instituto Dante Pazzanese de Cardiologia.
CliniCAl follow-uP And definitionS
The late follow-up was performed by medical chart 
review and/or direct telephone contact. The mean clinical 
follow-up was 945 days (2.6 ± 1.4 years). The primary 
objective was to evaluate the rate of major adverse 
cardiac events (MACE), defined as the occurrence of 
cardiovascular death, non-fatal acute myocardial in-
farction (AMI), and target vessel revascularisation. All 
deaths were considered cardiovascular unless a non-
cardiac cause could be clearly established. Non-fatal 
AMI was defined as an increase greater than three times 
the laboratory reference values of creatine kinase MB 
fraction (CK-MB), which did not involve death of the 
patient. Target lesion revascularisation was defined as 
new revascularisation by PCI or coronary artery bypass 
graft (CABG) of the segment previously treated with 
MGuardTM stent. Target vessel revascularisation was 
defined as new revascularisation by PCI or CABG of 
the vessel previously treated with MGuardTM stent. Stent 
thrombosis was defined according to the criteria of the 
Academic Research Consortium (ARC) as: definitive 
(pre sence of acute coronary syndrome with angiographic 
or anatomopathological confirmation of stent occlusion); 
probable (sudden death occurrence < 30 days after 
the index procedure or AMI in the treated myocardial 
territory without angiographic confirmation of stent 
occlusion); and possible (sudden death occurrence > 30 
days after the index procedure). Stent thrombosis was 
also classified according to the temporal occurrence, 
including the acute (< 24 hours post-procedure), subacute 
(between 24 hours and 30 days post-procedure), late 
(between one month and 12 months post-procedure), 
and very late (> 12 months post-procedure) phases. 
Angiographic success was defined as the achievement 
of TIMI 3 flow without dissection and residual stenosis 
< 50% in the treated segment after the procedure. 
Statistical Analysis
Qualitative variables were shown as frequencies 
and percentages, and quantitative variables as means 
and standard deviations. The occurrence of MACE as a 
function of time is described by Kaplan-Meier curves.
Figure 1 – Illustration showing the MGuardTM device.
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large number of patients: slowing of antegrade coronary 
flow (16.4%) and no reflow (8.2%) were the main com-
plications observed. At the end of the procedure, TIMI 
3 flow was achieved in 93.4% of cases, and angiographic 
success was 91.8%. Table 4 shows the data from QCA 
(n = 61). Mean lesion length and reference vessel diameter 
before the procedure were 13.2 ± 6.8 mm and 2.99 ± 
0.68 mm, respectively. At the end of the procedure, mean 
stenosis diameter was < 20%.
ReSultS
Mean age was 66.1 ± 13.7 years, 26.2% of patients 
were females, 32.3% had diabetes, and 49.2% had 
previous AMI. Regarding clinical presentation, 44.6% 
of the patients had acute coronary syndrome, including 
15.4% with STEMI (Table 1). Of the 66 initially consid-
e red lesions (one patient had two lesions treated in two 
distinct target vessels), 44 lesions (67.7% of cases) were 
located in bypass grafts. Regarding the characteristics 
of the lesions (n = 61), there was a high prevalence 
of thrombi (42.6%) and saphenous grafts degeneration 
(37.7%). Consequently, high-complexity lesions (type 
B2/C) were observed in most cases (85.2%). Further-
more, the prevalence of TIMI flow 0 or 1 before the 
procedure was 11.5% (Table 2).
During the procedure, no filters were used for distal 
protection in any case. Lesion pre-dilation was performed 
in 34.5% of cases; a total of 70 MGuardTM stents were 
implanted in 66 lesions (1.06 ± 0.2 lesions per stent), 
and post-dilation was performed in 60.6% of lesions. The 
values  of length, diameter, and nominal inflation pressure 
values of balloons and stents used are shown in Table 3. 
Angiographic complications were observed in a relatively 
Table 1 
Basal clinical characteristics
Variable n = 65
Age, years 66.1 ± 13.7
Female gender, n (%) 17 (26.2)
Diabetes, n (%) 21 (32.3)
Hypertension, n (%) 57 (87.7)
Dyslipidaemia, n (%) 45 (69.2)
Smoking, n (%) 23 (35.4)
Current 9 (13,9)
Previous AMI, n (%) 32 (49.2)
Previous percutaneous coronary 
intervention, n (%)
5 (7.7)
Previous CABG, n (%) 44 (67.7)
Family history of CAD, n (%) 5 (7.7)
Renal failure,a n (%) 26 (40)
Clinical presentation, n (%) 
Silent ischemia 10 (15.4)
Stable angina 26 (40)
ACSWSTE 19 (29.2)
STEMI 10 (15.4)
a Serum creatinine ≥ 1.5 mg/dL
AMI, acute myocardial infarction; CABG, coronary artery 
bypass graft; CAD, coronary artery disease; ACSWSTE, acute 
coronary syndrome without ST-segment elevation; STEMI, 
myocardial infarction with ST-segment elevation.
Table 2 
Angiographic data
n = 65a
Target-vessel, n (%)
ADA 9/65 (13.8)
Cx 3/65 (4.6)
RCA 9/65 (13.8)
Saphenous graft 44/65 (67.7)
Affected coronary segment, n (%)
Ostial 3/66 (4.5)
Proximal 30/66 (45.5)
Medium 27/66 (40.9)
Distal 6/66 (9.1)
Characteristics of the lesions, n (%)
Eccentricity 32/61 (52.5)
Calcium (moderate/severe) 9/61 (14.8)
Irregular borders 22/61 (36.1)
Ulcers 6/61 (9.8)
Aneurysm 2/61 (3.3)
Tortuosity (moderate/severe) 4/61 (6.6)
Bifurcation 2/61 (3.3)
Saphenous graft degeneration 23/61 (37.7)
Occlusion 6/61 (9.8)
Ectasia 27/61 (44.3)
Angulation (moderate/severe) 3/61 (4.9)
Thrombus 26/61 (42.6)
Type of lesion (ACC/AHA), n (%)
A/B1 9/61 (14.8)
B2/C 52/61 (85.2)
Pre-procedural coronary flow, n (%)
TIMI 0/1 7/61 (11.5)
TIMI 2/3 54/61 (88.5)
a 65 patients for a total of 66 lesions/coronary segments, of which 
61 were available for morphological and quantitative analyses.
ADA, anterior descending artery; Cx, circumflex artery; 
RCA, right coronary artery; ACC/AHA, American College of 
Cardiology/American Heart Association; TIMI, Thrombolysis 
in Myocardial Infarction.
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During the in-hospital phase, six patients had peri-
procedural myocardial infarction (five without Q-wave 
and one with Q-wave), but no other adverse events were 
observed until discharge. At the late clinical follow-up 
(mean duration 2.6 ± 1.4 years), cumulative rates of 
adverse events after discharge included cardiovascular 
death in 6.2% of patients, non-fatal AMI in 9.2%, 
target-vessel revascularisation in 12.3%, target-lesion 
revascularisation in 9.2%, and MACE in 23.1%. Regard-
ing stent thrombosis, the events classified as definitive/
probable occurred in 1.5% of patients (Table 5). Figure 
2 shows the MACE-free survival curve.
diSCuSSion
Several authors have published studies demonstrating 
the MGuardTM performance in different scenarios. Grube 
Table 3 
Data on the procedure
n = 65a
Radial access, n (%) 12/65 (18.5)
Antithrombin therapy, n (%)
Unfractionated heparin 62/65 (95.4)
Low-molecular weight heparin 3/65 (4.6)
Glycoprotein IIb/IIIa inhibitor 10/65 (15.4)
Predilation, n (%) 23 (34.8)
Nominal balloon extension, mm 16.4 ± 4.2
Nominal balloon diameter, mm 2.4 ± 0.4
Insufflation pressure, atm 10.9 ± 3.7
MGuardTM stent, n (%) 70/70 (100)
Nominal stent extension, mm 21.2 ± 7
Nominal stent diameter, mm 3.4 ± 0.4
Insufflation pressure, atm 14.3 ± 3.9
Post-dilation, n (%) 40 (60.6)
Nominal balloon extension, mm 13.9 ± 3.6
Nominal balloon diameter, mm 3.5 ± 0.4
Insufflation pressure, atm 14.6 ± 3.5
Angiographic complications, n (%)
Dissection 6/61 (9.8)
Slow flow 10/61 (16.4)
Distal embolisation 3/61 (4.9)
No reflow phenomenon 5/61 (8.2)
Abrupt vessel occlusion 0/61 (0)
Final TIMI flow 3, n (%) 57/61 (93.4)
Angiographic success, n (%) 56/61 (91.8)
a 65 patients for a total of 66 lesions/coronary segments, of which 
61 were available for morphologic and quantitative analysis.
Table 4 
Quantitative coronary angiography
n = 61 lesions
Pre-procedure
Lesion extension, mm 13.2 ± 6.8
 < 10 mm, n (%) 23 (37.7)
 10-20 mm, n (%) 31 (50.8)
 > 20 mm, n (%) 7 (11.4)
Reference diameter, mm 2.99 ± 0.68
Minimum lumen diameter, mm 1.03 ± 0.57
Stenosis diameter, % 67.1 ± 17.6
Post-procedure
Reference diameter, mm 3.08 ± 0.67
Minimum lumen diameter, mm 2.58 ± 0.51
Stenosis diameter, % 15.8 ± 9
Acute gain, mm 1.55 ± 0.63
Reference diameter (intrastent), mm 3.29 ± 0.69
Minimum lumen diameter 
(intrastent), mm
2.84 ± 0.49
Stenosis diameter (intrastent), % 12.9 ± 7.3
Acute gain (intrastent), mm 1.82 ± 0.54
Balloon-artery ratio 1.19±0.67
Table 5 
Clinical events (hierarchical classification)
Variable n = 65
Major adverse cardiac events (cardiovascular 
death, non-fatal AMI, and target-vessel 
revascularisation), n (%)
15/65 
(23.1)
Cardiovascular death, n (%) 4/65 (6.2)
Non-fatal acute myocardial infarction, n (%) 6/65 (9.2)
Target-vessel revascularisation, n (%) 8/65 (12.3)
Target-lesion revascularisation, n (%) 6/65 (9.2)
Definitive/probable thrombosis (ARC), n (%) 1/65 (1.5)
AMI, acute myocardial infarction; ARC, Academic Research 
Consortium.
et al.5 published a prospective study of 41 patients to 
evaluate the feasibility and safety of the MGuardTM stent 
during PCI. Clinical and laboratory monitoring were 
performed with cardiac biomarkers, electrocardiography 
(ECG), and coronary angiography at six months. In ap-
proximately half of the patients (56%), the target vessel 
was the bypass graft; however, no patients received 
glycoprotein IIb/IIIa inhibitors or distal embolic protec-
tion devices. Nevertheless, angiographic and procedure 
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success rates were 100% and 95%, respectively. At 
the six-month follow-up, 19.5% of patients underwent 
revascularisation of the target vessel. At the very late 
follow-up of these patients (12 to 27 months), there was 
only one additional target-vessel revascularisation. In 
the present analysis, which included 65 patients with 
complex clinical and angiographic profiles, 67.7% of 
cases involved bypass graft (half with degeneration 
morphology), 15.4% received glycoprotein IIb/IIIa inhibi-
tors, and none used a distal embolic protection device. 
At the end of the procedure, the angiographic success 
rate was 91.8%. At the very late follow-up (2.6 ± 1.4 
years), 12.3% of patients were submitted to target-vessel 
revascularisation. These late outcomes suggest accep-
table rates of target-vessel revascularisation, considering 
the location (bypass graft) and the complexity of the 
lesions, as well as the absence of a drug component 
in the MGuardTM stent. A study by Costa et al.,6 which 
included 30 patients with angiographic study protocol 
at six months, showed late lumen loss of 1.05 ± 0.77 
mm in bypass grafts (n = 16) and 0.95 ± 0.66 mm (n 
= 14) in native vessels treated with the MGuardTM stent. 
These values are similar to those found in studies with 
conventional bare-metal stents used in clinical practice 
and justify, at least in part, the rates of target-lesion/
target-vessel revascularisation observed in the abovemen-
tioned studies. Another relevant aspect is the absence 
of negative impact in terms of neointimal hyperplasia 
formation, due to the presence of the polymer coating 
on the MGuardTM stent, designed to prevent migration 
of thrombus to the distal bed during PCI.
Several studies also evaluated the use of the 
MGuardTM stent in patients during acute coronary 
syndrome. Stone et al.7 published a prospective ran-
domized study (Safety and Efficacy Study of MGuard 
Stent After a Heart Attack – MASTER), with 433 pa-
tients to evaluate the benefit of the MGuardTM stent in 
patients with STEMI submitted to PCI within 12 hours 
of symptom onset. The primary outcome was complete 
resolution of the ST-segment elevation, defined as a 
reduction > 70%. There were no differences in baseline 
patient characteristics between the groups; however, the 
group submitted to MGuardTM stenting had higher rates 
of TIMI 3 flow after the procedure (91.7% vs. 82.9%; 
P = 0.006), and higher rate of complete resolution of 
ST-segment elevation (57.8% vs. 44.7%; P = 0.008). 
Subgroup analysis showed no differences between 
them. Regarding clinical outcomes after 30 days, there 
was a tendency to decreased cardiovascular mortal - 
ity in the MGuardTM group (0 vs. 1.9%; P = 0.06), 
with no statistically significant difference for the other 
assessed outcomes. Still in the setting of acute coronary 
syndromes, Lindefjeld et al.8 published an analysis of 
15 patients undergoing MGuardTM stenting in situations 
of high thrombotic burden (53% during STEMI). No 
distal embolic protection filters were used, although 
40% of the PCIs were performed in saphenous vein 
bypass grafts, and TIMI 3 flow was obtained in all 
cases. In the present study, the rate of TIMI 3 flow after 
the procedure (93.4%) was similar to that in the group 
treated with the MGuardTM stent from the MASTER study 
(91.7%). These findings can be explained by the high 
prevalence of thrombus and embolic complications in 
the studies. Notably, outcomes with the MGuardTM stent 
were superior when compared to the control group 
in the MASTER study, suggesting efficacy of this stent 
in preventing distal embolisation when compared to 
conventional treatment.
The effectiveness of distal embolic protection devices 
in preventing thrombotic complications during PCI in 
saphenous vein bypass grafts has been extensively vali-
dated and incorporated into clinical practice. However, 
the use of such devices can be laborious and often 
impossible to perform, and adds time and cost to the 
procedure. It is noteworthy that such devices were not 
used during PCI in vein grafts in several studies with 
the MGuardTM stent; nevertheless, this measure does 
not appear to have compromised the results. The pos-
sibility of a therapeutic approach of lesions with high 
thrombotic burden, involving degenerated vein grafts, 
with a low-profile stent and without the need for em-
bolic protection devices is undoubtedly very attractive 
and desirable. Esteves et al.9 published a comparative, 
non-randomized trial on PCI in saphenous vein bypass 
grafts with 38 patients (16 in the MGuardTM group and 
22 in the bare-metal stent group, with use of distal 
embolic protection filter), which demonstrated that these 
devices were similar for the occurrence of MACE at 
30 days. Conversely, some consider that both devices 
could act synergistically, especially in cases with high 
thrombotic content. Even though most reports with 
Figure 2 – Curve of survival free from major adverse cardiac events.
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the MGuardTM stent demonstrate relatively high rates 
of procedural success despite the non-use of embolic 
protection devices in saphenous vein bypass grafts, there 
have been no formal recommendations for its isolated 
use to date, due to the lack of comparative analyses. 
Therefore, further, properly designed studies are needed 
in order to assess this possibility.
ConCluSionS
The late follow-up of patients with complex coro-
nary lesions treated with the MGuardTM stent showed 
low rates of target-lesion revascularisation and stent 
thrombosis.
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